Search

Showing total 4 results
Start Over Search Limiters Available in Library Collection Topic hiv-1 infection Publisher taylor & francis ltd
4 results

1. A delayed HIV-1 model with cell-to-cell spread and virus waning.

Author

Li, Bing and Jiao, Feng

Subjects
BASIC reproduction number, VIRAL transmission, VIRUS diseases, VIRAL load
Abstract

In this paper, we propose and analyse a delayed HIV-1 model with both viral and cellular transmissions and virus waning. We obtain the threshold dynamics of the proposed model, characterized by the basic reproduction number R 0 . If R 0 < 1 , the infection-free steady state is globally asymptotically stable; whereas if R 0 > 1 , the system is uniformly persistent. When the delays are positive, we show that the intracellular delays in both viral and cellular infections may lead to stability switches of the infected steady state. Both analytical and numerical results indicate that if the effect of cell-to-cell transmission is ignored, then the risk of HIV-1 infection will be underestimated. Moreover, the viral load of model without virus waning is higher than the one of model with virus waning. These results highlight the important role of two ways of viral transmission and virus waning on HIV-1 infection. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

3. Drug safety profile of integrase strand transfer inhibitors

Author

Gutierrez, MD, Mateo, MG, Vidal, F, and Domingo, P

Subjects
integrase strand transfer inhibitors, safety, integrase inhibitors, antiretroviral therapy, elvitegravir, toxicity, HIV-1 infection, raltegravir, dolutegravir
Abstract

Introduction: HIV-1 integrase strand transfer inhibitors (INSTIs) are a novel class of antiretroviral drugs with a good safety profile. Several INSTIs have been developed clinically. Areas covered: The purpose of this review is to examine the safety data of the three FDA-approved INSTIs: Raltegravir (RAL), Elvitegravir (EVG) and Dolutegravir (DTG). The most relevant papers related to the safety profile of integrase inhibitors were selected and summarized. Expert opinion: INSTIs have demonstrated a favorable safety profile in Phase II and III trials. The most common clinical adverse events reported were diarrhea, nausea and headache. DTG and cobicistat, a component of Stribild (TM), increase serum creatinine and decrease estimated creatinine clearance due to inhibition of active tubular secretion of creatinine without affecting renal glomerular function. INSTIs intrinsic potency, together with an outstanding safety profile, preludes an important role for these drugs to build up highly active antiretroviral treatment (HAART) in the near future.

Published
2014

4. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection

Author

Mateo, MG, Gutierrez, MD, Vidal, F, and Domingo, P

Subjects
AIDS, antiretroviral treatment, safety, stavudine, toxicity, lamivudine, HIV-1 infection
Abstract

Introduction: The lamivudine (3TC) + stavudine (d4T) combination is still widely used as part of first-line therapy for HIV-1-infected patients in low-resource countries. This review is intended to assess the benefits and risks in terms of safety of d4T + 3TC-based combination antiretroviral therapy (ART) for the treatment of HIV-1 infection. Areas covered: The most relevant papers related to the safety of d4T + 3TC-based ART were selected and summarized. Expert opinion: In industrialized countries, the 3TC + d4T combination is not recommended for initial therapy because of long-term metabolic toxicities associated with d4T. In developing countries, it may have a role in the treatment of HIV-infected patients if there is no other chance for starting antiretroviral therapy.

Published
2012